Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress

Journal of Molecular Cell Biology

Volumn 4, Issue 5, 2012, Pages 284-293

  Brandl, André ^a   Wagner, Tobias ^a   Uhlig, Katharina M ^a,b   Knauer, Shirley K ^c   Stauber, Roland H ^d   Melchior, Frauke ^e   Schneider, Günter ^f   Heinzel, Thorsten ^a   Krämer, Oliver H ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e GERMAN CANCER RESEARCH CENTER   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

acetylation; apoptosis; HDAC2; p53; SUMO

Indexed keywords

DOXORUBICIN; HISTONE DEACETYLASE 2; LYSINE; PROTEIN P53; SUMO 1 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CELL FATE; CELL LINE; CELL STRESS; CONTROLLED STUDY; DEACETYLATION; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; GENE EXPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SUMOYLATION; TUMOR SUPPRESSOR GENE;

ACETYLATION; APOPTOSIS; CELL LINE, TUMOR; DNA DAMAGE; HCT116 CELLS; HEK293 CELLS; HELA CELLS; HISTONE DEACETYLASE 2; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SUMOYLATION; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867426439     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjs013     Document Type: Article

References (30)

1. Baus, D., Nonnenmacher, F., Jankowski, S., et al. (2009). STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia 23, 1885-1893.
2. Beckerman, R., and Prives, C. (2010). Transcriptional regulation by p53. Cold Spring Harb. Perspect. Biol. 2, a000935.
3. Brandl, A., Heinzel, T., and Kramer, O.H. (2009). Histone deacetylases: salesmen and customers in the post-translational modification market. Biol. Cell 101, 193-205.
4. Brooks, C.L., and Gu, W. (2006). p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21, 307-315.
5. Bunz, F., Dutriaux, A., Lengauer, C., et al. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501.
6. Chan, W.M., Siu, W.Y., Lau, A., et al. (2004). How many mutant p53 molecules are needed to inactivate a tetramer? Mol. Cell. Biol. 24, 3536-3551.
7. Chang, H.H., Chiang, C.P., Hung, H.C., et al. (2009). Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol. 45, 610-614.
8. Chao, C., Wu, Z., Mazur, S.J., et al. (2006). Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell. Biol. 26, 6859-6869.
9. Fakhry, H., Miyamoto, T., Kashima, H., et al. (2010). Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells. Hum. Pathol. 41, 848-858.
10. Fritsche, P., Seidler, B., Schuler, S., et al. (2009). HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 58, 1399-1409.
11. Gareau, J.R., and Lima, C.D. (2010). The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 11, 861-871.
12. Geiss-Friedlander, R., and Melchior, F. (2007). Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 8, 947-956.
13. Harms, K.L., and Chen, X. (2007). Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 67, 3145-3152.
14. Hay, R.T. (2005). SUMO: a history of modification. Mol. Cell 18, 1-12.
15. Huang, B.H., Laban, M., Leung, C.H., et al. (2005). Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 12, 395-404.
16. Baus, D., Nonnenmacher, F., Jankowski, S., et al. (2009). STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia 23, 1885-1893.
17. Beckerman, R., and Prives, C. (2010). Transcriptional regulation by p53. Cold Spring Harb. Perspect. Biol. 2, a000935.
18. Brandl, A., Heinzel, T., and Kramer, O.H. (2009). Histone deacetylases: salesmen and customers in the post-translational modification market. Biol. Cell 101, 193-205.
19. Brooks, C.L., and Gu, W. (2006). p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21, 307-315.
20. Bunz, F., Dutriaux, A., Lengauer, C., et al. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501.
21. Chan, W.M., Siu, W.Y., Lau, A., et al. (2004). How many mutant p53 molecules are needed to inactivate a tetramer? Mol. Cell. Biol. 24, 3536-3551.
22. Chang, H.H., Chiang, C.P., Hung, H.C., et al. (2009). Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol. 45, 610-614.
23. Chao, C., Wu, Z., Mazur, S.J., et al. (2006). Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell. Biol. 26, 6859-6869.
24. Fakhry, H., Miyamoto, T., Kashima, H., et al. (2010). Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells. Hum. Pathol. 41, 848-858.
25. Fritsche, P., Seidler, B., Schuler, S., et al. (2009). HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 58, 1399-1409.
26. Gareau, J.R., and Lima, C.D. (2010). The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 11, 861-871.
27. Geiss-Friedlander, R., and Melchior, F. (2007). Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 8, 947-956.
28. Harms, K.L., and Chen, X. (2007). Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 67, 3145-3152.
29. Hay, R.T. (2005). SUMO: a history of modification. Mol. Cell 18, 1-12.
30. Huang, B.H., Laban, M., Leung, C.H., et al. (2005). Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.Cell Death Differ. 12, 395-404.